2008
DOI: 10.1210/en.2008-0318
|View full text |Cite
|
Sign up to set email alerts
|

The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine/Paracrine Modulator of Cardiac Inotropism and Lusitropism

Abstract: Circulating levels of catestatin (Cts; human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga-null mice with Cts prevents blood pressure elevation, indicating a direct role of Cts in preventing hypertension. This notable vasoreactivity prompted us to test the direct cardiovascular effects and mechanisms of action of wild-type (WT) Cts and naturally occurring human v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

8
177
0
7

Year Published

2009
2009
2017
2017

Publication Types

Select...
5
3

Relationship

2
6

Authors

Journals

citations
Cited by 141 publications
(192 citation statements)
references
References 51 publications
8
177
0
7
Order By: Relevance
“…CST acts as a negative regulator of hypertension, 7 inotropy, and lusitropy. 20 CST Figure 6. CST-induced effects on ECs are mediated by bFGF.…”
Section: Discussionmentioning
confidence: 99%
“…CST acts as a negative regulator of hypertension, 7 inotropy, and lusitropy. 20 CST Figure 6. CST-induced effects on ECs are mediated by bFGF.…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, in order to evaluate the effective role of CST in cardioprotection, in additional experiments, hearts were perfused with heat-inactivated CST [3] at the identical concentration of active CST (75nM), for 20-min at the beginning of reperfusion.…”
Section: Additional Experimentsmentioning
confidence: 99%
“…Actually, CST is known to counteract exaggerated β-adrenergic activity, which is relevant part of the neuroendocrine scenario of heart failure [1][2][3][4], and to dilate human vessels in vivo [16], thus exerting positive effects on cardiac afterload. In line with these evidences and since β-blockade is largely used as post-ischaemic treatment, the present work suggests that exogenous CST may provide new tool for pharmacological postconditioning.…”
Section: Clinical Considerationsmentioning
confidence: 99%
See 1 more Smart Citation
“…[30] Catestatin is the first known endogenous compound able to inhibit in vitro catecholamine release from both chromaffin cells and noradrenergic neurons by acting as a non-competitive nicotinic cholinergic antagonist. [31] Angelone et al, (2008) [32] hypothesized that circulating levels of catestatin decreased in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice increases blood pressure and pretreatment of Chga-null mice with Cts prevents blood pressure elevation indicating a direct role of Cts in preventing hypertension.…”
Section: Discussionmentioning
confidence: 99%